FDA Purple Book · Reference family
nofetumomab (Verluma)
nofetumomab is an FDA-licensed reference biologic from Boehringer Ingelheim Pharma GmbH & Co. KG. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1998
Reference approved
Reference product
351(a)BLA 103769
Verluma nofetumomab
Boehringer Ingelheim Pharma GmbH & Co. KG
- Approved
- Oct 13, 1998
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for nofetumomab, in chronological order.
Reference approval
Approval date of the reference nofetumomab product.
28 yr ago
Frequently asked questions
Are there biosimilars approved for nofetumomab (Verluma)?
No 351(k) biosimilars or interchangeable biosimilars referencing nofetumomab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.